NCT06350279View on ClinicalTrials.gov

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

August 2, 2024

Study Completion Date

September 29, 2024

Conditions

Healthy

Interventions

DRUG

HSK39297

50-600mg

Trial Locations (1)

Unknown

Beijing Tongren Hospital, Beijing

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY